Payment overview · 2025
General Payments
$650.03
29 reported records · 9 companies
Healthcare provider profile · identity verified
Dorit Ben-Moha, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · JERICHO, NY · NPI 1831288851
Verified facts
What the public records show
CMS Open Payments records show Dorit Ben-Moha, DO received $650.03 in general payments during 2025 across 29 reported records.
Astellas Pharma US Inc accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $283.43 | 43.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $111.05 | 17.1% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.83 | 8.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $50.44 | 7.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.36 | 7.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.30 | 7.6% | 3 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.73 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.65 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.24 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $465.04 | 27 |
| Education | $184.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $98.44 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $91.92 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.83 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.36 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.24 | 2 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 100 |
| Omeprazole | Omeprazole | 488 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 79 |
| Simvastatin | Simvastatin | 437 | 60 |
| Famotidine | Famotidine | 401 | 55 |
| Alendronate Sodium | Alendronate Sodium | 380 | 52 |
| Losartan Potassium | Losartan Potassium | 344 | 73 |
| Montelukast Sodium | Montelukast Sodium | 296 | 39 |
| Lactulose | Lactulose | 286 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 216 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 35 |
| Midodrine Hcl | Midodrine Hcl | 199 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 184 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 36 |
| Potassium Chloride | Potassium Chloride | 176 | 34 |
| Nystatin | Nystatin | 172 | 49 |
| Furosemide | Furosemide | 170 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 164 | 17 |
| Gabapentin | Gabapentin | 152 | 37 |
| Glycopyrrolate | Glycopyrrolate | 148 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 23 |
| Linzess | Linaclotide | 138 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 29 |
| Metoclopramide Hcl | Metoclopramide Hcl | 123 | 12 |
| Metformin Hcl | Metformin Hcl | 116 | 19 |
| Ketoconazole | Ketoconazole | 107 | 22 |
| Eliquis | Apixaban | 105 | 17 |
| Levetiracetam | Levetiracetam | 105 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 24 |
| Meloxicam | Meloxicam | 102 | 20 |
| Baclofen | Baclofen | 99 | 12 |
| Azithromycin | Azithromycin | 98 | 69 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 13 |
| Lisinopril | Lisinopril | 94 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 89 | 73 |
| Mirtazapine | Mirtazapine | 85 | 26 |
| Sucralfate | Sucralfate | 85 | suppressed |
| Finasteride | Finasteride | 84 | suppressed |
| Ezetimibe | Ezetimibe | 81 | 18 |
| Ozempic | Semaglutide | 79 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 77 | 14 |
| Diazepam | Diazepam | 74 | 35 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 68 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 19 |
| Budesonide | Budesonide | 55 | suppressed |
| Atenolol | Atenolol | 54 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 52 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Vascepa | Icosapent Ethyl | 51 | suppressed |
| Methylprednisolone | Methylprednisolone | 50 | 35 |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Mupirocin | Mupirocin | 47 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 34 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 44 | suppressed |
| Lorazepam | Lorazepam | 44 | 11 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | suppressed |
| Carvedilol | Carvedilol | 40 | suppressed |
| Risperidone | Risperidone | 39 | 12 |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 11 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 13 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 29 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 11 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Prolia | Denosumab | 26 | 17 |
| Repaglinide | Repaglinide | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Desmopressin Acetate | Desmopressin Acetate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Klayesta | Nystatin | 24 | 11 |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 23 | suppressed |
| Tobramycin | Tobramycin | 23 | 20 |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Abacavir | Abacavir Sulfate | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Fosamprenavir Calcium | Fosamprenavir Calcium | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $650.03 · 29 records | Astellas Pharma US Inc | APLENZIN, FARXIGA, IBSRELA, MOUNJARO, NEXLETOL, TRELEGY ELLIPTA, Veozah, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error